SubHero Banner

Shingrix (Zoster vaccine recombinant, adjuvanted) – Expanded indication

July 26, 2021 - GlaxoSmithKline announced the FDA approval of Shingrix (Zoster vaccine recombinant, adjuvanted), for prevention of herpes zoster (HZ) (shingles) in adults aged 18 years and older who are or will be at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy.

Download PDF